

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]

Vaishampayan UN. *Core Evidence*. 2014;9:61–67.

On page 62, line 6 of the Introduction section and page 67, line 2 of the Disclosure statement, “Exelexis Inc.” should read “Exelixis Inc.”.

Core Evidence

Dovepress

Publish your work in this journal

Core Evidence is an international, peer-reviewed open-access journal evaluating the evidence underlying the potential place in therapy of drugs throughout their development lifecycle from preclinical to post-launch. The focus of each review is to evaluate the case for a new drug or class in outcome terms in specific indications and patient groups.

Submit your manuscript here: <http://www.dovepress.com/core-evidence-journal>

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

